Company intelligence · Nasdaq: SLN

Silence Therapeutics: pipeline and clinical trials

Silence Therapeutics develops small interfering RNA drugs, including zerlasiran for lipoprotein(a). In October 2026 it agreed to be acquired by Merck KGaA, Darmstadt, Germany, with closing expected in the first quarter of 2027.

Legal name (SEC)Silence Therapeutics plc
ListingNasdaq: SLN
HeadquartersLondon, United Kingdom
SEC filingsEDGAR (CIK 1479615)
Focus areasCardiovascular disease (lipoprotein(a)), Hematology

Key points

  • Silence's lead cardiovascular drug, zerlasiran, completed Phase 2 with Lp(a) reductions of more than 80%. No Phase 3 trial is registered.
  • Silence reports that it completed zerlasiran Phase 3 readiness work in 2025 (company-reported).
  • On October 19, 2026, Silence announced a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, through a U.K. scheme of arrangement, expected to close in Q1 2027 (company-reported).
  • Its one active trial on ClinicalTrials.gov is a Phase 1/2 study of SLN124 in polycythemia vera, a blood disorder.
  • Merck KGaA is unrelated to Merck & Co. of Rahway, New Jersey, which developed enlicitide.

Tracked drug profiles

Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.

Active clinical trials

ClinicalTrials.gov lists 1 active trials with Silence Therapeutics as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "Silence Therapeutics plc" or "Silence Therapeutics GmbH".

By phase

Phase 1/21

Most common conditions

  • Polycythemia Vera (1)

Conditions as registered by the sponsor; one trial can list several.

See this sponsor’s trials on ClinicalTrials.gov

Pipeline

  • Zerlasiran (SLN360), for elevated lipoprotein(a): Phase 2 complete, with no registered Phase 3.
  • SLN124, for polycythemia vera: in a Phase 1/2 trial, the company's only active trial in the registry.

The acquisition

Silence's agreement to be acquired by Merck KGaA changes who will decide zerlasiran's future. The sources we reviewed do not state the acquirer's plans for the program. A Phase 3 cardiovascular outcomes trial would be a multi-year, multi-thousand-patient commitment, and it would start behind the olpasiran and lepodisiran trials already underway.

What to watch

  • Completion of the acquisition, expected in Q1 2027 (company-reported).
  • Any registration of a zerlasiran Phase 3 trial.

Partnerships and corporate events

  • Merck KGaA, Darmstadt, Germany: definitive agreement to acquire Silence, announced October 19, 2026; expected to close in Q1 2027 subject to customary conditions. Company-reported

Recent milestones

  1. Dec 17, 2024Zerlasiran Phase 2 results published: Lp(a) reductions of 81% to 86% versus placebo through week 36. Peer-reviewed
  2. Oct 19, 2026Silence agrees to be acquired by Merck KGaA, Darmstadt, Germany. Company-reported
  3. Nov 12, 2026Silence reports third-quarter 2026 results, citing the pending acquisition. Company-reported

Sources

  1. SEC EDGAR: Silence Therapeutics plc filings (CIK 1479615).Regulator
  2. Silence Therapeutics plc. Form 8-K, Exhibit 99.1 (November 12, 2026).Company-reported
  3. Nissen SE, et al. Zerlasiran, a small-interfering RNA targeting lipoprotein(a): a Phase 2 randomized clinical trial. JAMA. 2024;332(23):1992–2002.Peer-reviewed
  4. ClinicalTrials.gov. SLN124 in polycythemia vera (NCT05499013).Registry
  5. ClinicalTrials.gov: active trials with this lead sponsorRegistry

This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.